{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:31:18Z","timestamp":1787225478692,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.therap.2026.07.003","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:19:06Z","timestamp":1783725546000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anhedonia and neuropsychotropics: A pharmacovigilance-pharmacodynamic study"],"prefix":"10.1016","author":[{"given":"Jean-Louis","family":"Montastruc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2026.07.003_bib0140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.9758\/cpn.23.1086","article-title":"Anhedonia and depressive disorders","volume":"21","author":"Serreti","year":"2023","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"10.1016\/j.therap.2026.07.003_bib0145","first-page":"e70088","article-title":"Anhedonia: current and future treatments","volume":"4","author":"Serreti","year":"2025","journal-title":"Psychiatry Clin Neurosci Rep"},{"key":"10.1016\/j.therap.2026.07.003_bib0150","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00002018-200730080-00001","article-title":"Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore","volume":"30","author":"Hauben","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2026.07.003_bib0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.therap.2023.10.007","article-title":"Drug-induced diseases: a worrying, neglected, preventable, serious and costly epidemic","volume":"79","author":"Montastruc","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2026.07.003_bib0160","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40264-025-01642-6","article-title":"VigiBase: resource profile update with a summary of global patterns and trends in adverse event reports for medicines and vaccines","volume":"49","author":"Brand","year":"2026","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2026.07.003_bib0165","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.euroneuro.2015.07.010","article-title":"Role of serotonin 5-HT2C and histamine H 1 receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase","volume":"25","author":"Montastruc","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.therap.2026.07.003_bib0170","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/bcp.13145","article-title":"An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders","volume":"83","author":"Nguyen","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2026.07.003_bib0175","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s40264-018-0693-8","article-title":"Role of serotonin transporter in antidepressant-induced diabetes mellitus: a pharmacoepidemiological-pharmacodynamic study in VigiBase\u00ae","volume":"41","author":"Nguyen","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2026.07.003_bib0180","series-title":"Medical dictionary for regulatory activities","year":"2026"},{"key":"10.1016\/j.therap.2026.07.003_bib0185","series-title":"Anatomical Therapeutic Chemical (ATC) Classification","year":"2026"},{"key":"10.1016\/j.therap.2026.07.003_bib0190","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2026.07.003_bib0195","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2026.07.003_bib0200","series-title":"IUPHAR\/BPS guide to pharmacology","year":"2026"},{"key":"10.1016\/j.therap.2026.07.003_bib0205","series-title":"Goodman and Gilman's the pharmacological basis of therapeutics","first-page":"343","article-title":"Drug therapy of depression and anxiety disorders","author":"O\u2019Donnel","year":"2023"},{"key":"10.1016\/j.therap.2026.07.003_bib0210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jad.2017.05.048","article-title":"Emotional blunting with antidepressant treatments: a survey among depressed patients","volume":"221","author":"Goodwin","year":"2017","journal-title":"J Affect Dis"},{"key":"10.1016\/j.therap.2026.07.003_bib0215","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jpsychires.2023.01.014","article-title":"Does partial blockade of dopamine D2 receptors with Amisulpride cause anhedonia? An experimental study in healthy volunteers","volume":"158","author":"Berg","year":"2023","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.therap.2026.07.003_bib0220","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/026988119300700412","article-title":"Neuroleptic-induced deficit syndrome: old problem, new challenge","volume":"7","author":"Lader","year":"1993","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.therap.2026.07.003_bib0225","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0447.1994.tb05825.x","article-title":"Neuroleptics and the neuroleptic-induced deficit syndrome","volume":"380","author":"Lewander","year":"1994","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.therap.2026.07.003_bib0230","series-title":"Goodman and Gilman's the pharmacological basis of therapeutics","first-page":"357","article-title":"Pharmacotherapy of psychosis and mania","author":"Meyer","year":"2023"},{"key":"10.1016\/j.therap.2026.07.003_bib0235","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejphar.2014.11.044","article-title":"The dark side of emotion: the addiction perspective","volume":"753","author":"Koob","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.therap.2026.07.003_bib0240","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.biopsych.2012.01.027","article-title":"Endogenous opioid release in the human brain reward system induced by acute amphetamine administration","volume":"72","author":"Colasanti","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.therap.2026.07.003_bib0245","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1017\/S1461145714000704","article-title":"Amphetamine induced endogenous opioid release in the human brain detected with [11C]carfentanil PET: replication in an independent cohort","volume":"17","author":"Mick","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.therap.2026.07.003_bib0250","doi-asserted-by":"crossref","first-page":"1103739","DOI":"10.3389\/fpsyt.2023.1103739","article-title":"Anhedonia modulates benzodiazepine and opioid demand among persons in treatment for opioid use disorder","volume":"14","author":"Greenwald","year":"2023","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2026.07.003_bib0255","series-title":"Goodman and Gilman's the pharmacological basis of therapeutics","first-page":"444","article-title":"Opioid analgesics","author":"Jutkiewicz","year":"2023"},{"key":"10.1016\/j.therap.2026.07.003_bib0260","first-page":"1166","article-title":"Reward sensitivity in patients receiving opioid agonist and antagonist treatment for opioid use disorder: an observational study","volume":"10","author":"Tr\u00f8stheim","year":"2025","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"10.1016\/j.therap.2026.07.003_bib0265","series-title":"Goodman and Gilman's the pharmacological basis of therapeutics","first-page":"531","article-title":"Drug use disorders and addiction","author":"Konradi","year":"2023"},{"key":"10.1016\/j.therap.2026.07.003_bib0270","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:21:31Z","timestamp":1787224891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595726000788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"alternative-id":["S0040595726000788"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2026.07.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anhedonia and neuropsychotropics: A pharmacovigilance-pharmacodynamic study","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2026.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}